Ravelcare launches Ravel PRO, AI skincare range; FY26 revenue up 7.9%
- Ravelcare launched Ravel PRO haircare range, contributing ~20% incremental revenue in July
- FY26 revenue rose 7.9% to ₹2,695.43 lakhs; PAT reached ₹515.40 lakhs
- AI diagnostic skincare range planned for H2FY27 launch
- Company remains debt-free with net worth of ₹3,740.84 lakhs
- IPO proceeds for manufacturing integration held in fixed deposits pending finalisation

*this image is generated using AI for illustrative purposes only.
Ravelcare launched Ravel PRO and announced an AI diagnostic skincare range on August 26, 2026. The new haircare line contributed roughly 20% incremental revenue in its first full month of July. This expansion targets both domestic and international consumers across e-commerce and quick-commerce platforms.
Product Launch Details
The company filed an intimation under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations with BSE Limited. The filing details the launch of Ravel PRO, a dermatologist-developed range of twelve products addressing hair fall, dandruff, damage repair, hair growth, and premature greying.
Key product highlights include:
- Zero Hairfall Shampoo and Conditioner using adenosine-peptide technology
- Zero Dandruff range featuring ketoconazole and salicylic acid
- Hyaluronic Repair Shampoo and Conditioner for damage repair
- Anti Grey Serum claiming up to 93% reduction in premature greying
The Anti-Grey Serum alone sold approximately 3,500 units in its first thirty days. Two additional PRO products are scheduled for launch in September. The AI-led diagnostic skincare range is planned for the second half of FY27.
Financial Performance
For FY26, the company reported revenue of ₹2,695.43 lakhs, representing a 7.9% increase. Profit after tax stood at ₹515.40 lakhs. The balance sheet shows no debt and a net worth of ₹3,740.84 lakhs.
| Metric | FY26 Value |
|---|---|
| Revenue | ₹2,695.43 lakhs |
| Revenue Growth | 7.9% |
| Profit After Tax | ₹515.40 lakhs |
| Net Worth | ₹3,740.84 lakhs |
| Debt Status | No debt |
The second half of FY26 was softer than the first half. Management reduced marketing spend by 19% compared to the previous year's second half to focus on IPO completion, R&D, and new category development. These activities did not contribute to revenue in H2FY26 but laid the groundwork for the current expansion.
Capital Allocation and Future Plans
The December 2025 IPO raised ₹2,410.20 lakhs (₹2,191.10 lakhs net of issue expenses). Funds allocated for backward integration into manufacturing remain unutilised and are held in bank fixed deposits earning interest. Management plans to finalise the plant's scale and configuration after stabilising the new product launches.
The company secured more favourable pricing from its existing manufacturing partner, ensuring no cost impact during recent global supply-chain disruptions. Advance planning of inputs and inventory protected product costs and supply continuity.
Historical Stock Returns for Ravelcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +5.77% | -1.08% | -8.56% | -33.77% | 0.0% | 0.0% |
How will the upcoming AI diagnostic skincare range in H2 FY27 differentiate Ravelcare from established dermatological competitors in the Indian market?
What is the timeline for utilizing the unspent IPO proceeds for backward integration, and how will owning manufacturing capacity impact long-term gross margins?
Given the 19% reduction in marketing spend during H2 FY26, what specific customer acquisition strategies will drive the projected revenue growth from the new PRO line?





























